Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Gamida Cell Ltd. | 241,977 | reported | 31 Jan 2024 | tx 10+424,977 |
| Kalaris Therapeutics, Inc. | 70,000 | reported | 06 Jun 2024 | tx 4+142,500 |
| ABEONA THERAPEUTICS INC. | 35,938 | reported | 20 May 2020 | tx 2+78,973 |
| Cabaletta Bio, Inc. | 22,725 | reported | 21 Jan 2026 | tx 8+176,725−66,000 |
| 4D Molecular Therapeutics, Inc. | 22,500 | reported | 17 Jun 2025 | tx 5+112,500 |
| UroGen Pharma Ltd. | 10,000 | reported | 07 Jun 2021 | tx 3+30,000 |
| PHARMACYCLICS INC | 0 | reported | 26 May 2015 | tx 10+162,500−168,284 |
| Principia Biopharma Inc. | 0 | reported | 28 Sept 2020 | tx 6+61,430−30,715 |
| TCR2 THERAPEUTICS INC. | 0 | reported | 01 Jun 2023 | tx 8+48,268−48,268 |
| Kite Pharma, Inc. | 0 | reported | 03 Oct 2017 | tx 13+257,600−268,672 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 21 Jan 2026 | PURCHASE | Cabaletta Bio, Inc. | 22,725 | 2.21 USD | first after silence |
| 17 Jun 2025 | GRANT_AWARD | 4D Molecular Therapeutics, Inc. | 22,500 | 0.00 USD | deriv |
| 09 Jun 2025 | GRANT_AWARD | Cabaletta Bio, Inc. | 22,000 | 0.00 USD | deriv |
| 19 May 2025 | OTHER | Cabaletta Bio, Inc. | 44,000 | 0.00 USD | deriv |
| 19 May 2025 | GRANT_AWARD | Cabaletta Bio, Inc. | 22,000 | 0.00 USD | deriv |
| 19 May 2025 | OTHER | Cabaletta Bio, Inc. | 22,000 | 0.00 USD | deriv |
| 19 May 2025 | GRANT_AWARD | Cabaletta Bio, Inc. | 44,000 | 0.00 USD | deriv |
| 06 Jun 2024 | GRANT_AWARD | Kalaris Therapeutics, Inc. | 35,000 | 0.00 USD | |
| 03 Jun 2024 | GRANT_AWARD | Cabaletta Bio, Inc. | 22,000 | 0.00 USD | deriv |
| 21 May 2024 | GRANT_AWARD | 4D Molecular Therapeutics, Inc. | 22,500 | 0.00 USD | deriv |
| 31 Jan 2024 | GRANT_AWARD | Gamida Cell Ltd. | 200,000 | 0.00 USD | |
| 21 Jul 2023 | GRANT_AWARD | Cabaletta Bio, Inc. | 44,000 | 0.00 USD | deriv |
| 01 Jun 2023 | OTHER | TCR2 THERAPEUTICS INC. | 4,177 | 0.00 USD | deriv |
| 01 Jun 2023 | OTHER | TCR2 THERAPEUTICS INC. | 15,191 | 0.00 USD | deriv |
| 01 Jun 2023 | OTHER | TCR2 THERAPEUTICS INC. | 12,100 | 0.00 USD | deriv |
| 01 Jun 2023 | OTHER | TCR2 THERAPEUTICS INC. | 16,800 | 0.00 USD | deriv |
| 23 May 2023 | GRANT_AWARD | 4D Molecular Therapeutics, Inc. | 22,500 | 0.00 USD | deriv |
| 11 May 2023 | GRANT_AWARD | Kalaris Therapeutics, Inc. | 35,000 | 0.00 USD | |
| 20 Mar 2023 | GRANT_AWARD | Gamida Cell Ltd. | 17,000 | 0.00 USD | deriv |
| 08 Feb 2023 | GRANT_AWARD | Gamida Cell Ltd. | 28,300 | 0.00 USD | |
| 08 Feb 2023 | GRANT_AWARD | Gamida Cell Ltd. | 56,600 | 0.00 USD | deriv |
| 15 Dec 2022 | GRANT_AWARD | TCR2 THERAPEUTICS INC. | 16,800 | 0.00 USD | deriv |
| 18 Nov 2022 | GRANT_AWARD | Gamida Cell Ltd. | 2,000 | 0.00 USD | |
| 18 Nov 2022 | GRANT_AWARD | Gamida Cell Ltd. | 9,500 | 0.00 USD | deriv |
| 30 Sept 2022 | PURCHASE | Gamida Cell Ltd. | 9,677 | 1.55 USD |
1 purchase reported after at least 12 months of silence — most recent on 21 Jan 2026.